Open in interactive viewer → charts, metric popovers & call review

Fennec's Record Quarter Has a Quiet Second Number

A 56% headline and a 30% EBITDA margin deserve the applause — but an 8% sequential crawl and a vanished Norgine update are the subtler story.
FENC · Earnings Call · 2026-11-12

The headline is 56%; the tell is 8%

Chief financial officer Robert Andrade opened the quarter with a flourish: “Fennec just reported the best commercial quarter in its history.” — Robert C. Andrade, Chief Financial Officer · 2026-11-12 Net product sales of $19.4 million were up roughly 56% year over year from $12.5 million, adjusted EBITDA hit a record $5.8 million (30% of net product sales, versus $2.0 million and 16% a year ago), EPS flipped to $0.12 from a $0.02 loss, and the balance sheet carries $48.7 million of cash with no debt. The operating leverage is genuine — Andrade's own framed it as "our EBITDA grew by $3 million on a revenue growth of $2.3 million," and the fundamentals agree that a fixed-cost base is now throwing off profit where it once threw off losses: operating income swung from a long stretch below zero to roughly $2 million on the back of a revenue line that went from essentially nothing to $18 million in the prior quarter. But the number a room full of analysts actually reached for was the sequential one. Revenue walked up $15 million in Q1, $18 million in Q2, and $19.4 million in Q3 — roughly a 20% sequential gain that decelerated to around 8%. The 56% year-over-year figure is partly a lap of a soft base. Chase Knickerbocker of Craig-Hallum put the tension bluntly: “Enrollments up 23%; completed infusions up 58%. Both of those were greater than the sequential change in revenue from Q2 to Q3. Can you just help us understand kind of why?” — Chase Knickerbocker, Analyst · 2026-11-12 Andrade's answer — infusion timing, and a revenue mix that blends academic, outpatient and select government patients — is honest, but it is also the explanation for why the funnel's leading indicators can sprint while the top line walks.

Entering the fourth quarter of 2026, we have the largest number of patients planned infusions, and planned vials being carried over from the third quarter. Importantly, we have strong visibility into the strength of our fourth quarter.

Robert C. Andrade, Chief Financial Officer · 2026-11-12
That carryover claim is the company's answer to the deceleration, and it is not nothing — management says October was strong and treats Q4 visibility as unusually good. But a reader should hold it lightly: "strong visibility" is a verbal promise, and the sequential slope is the hard number.

Project Ignite's second act: from sales force to formulary

What changed this quarter shows up clearly in the language. In the prior two calls the keyword slate was about people and buildout — medical affairs, sales force, new reps, Project Ignite. This quarter those fade and a different vocabulary takes over: academic center, formulary win, Fennec HEARS, new account, existing account. The hiring story is done; the conversion story has begun. The freshest datapoint is a formulary win at a large Midwestern academic center and its home-infusion service — a single institution the CFO says holds "potentially hundreds of patients." Management was careful to note it was not a Q3 revenue contributor, which is precisely why it matters: it is optionality, not history. Underneath sits a bigger reach claim — “we went from about 1300 physicians and accounts up to 5000 in our targets when we expanded these territories.” — Jeffrey S. Hackman, Chief Executive Officer · 2026-11-12 The patient-services hub did its part, with patient enrollment into Fennec HEARS up 23% and completed infusions up 58% quarter over quarter. And a useful new disclosure: “testicular cancer, that makes up a little north of half of our business today.” — Robert C. Andrade, Chief Financial Officer · 2026-11-12 Prior calls described testicular plus cervical plus head-and-neck as over 80% of the business without isolating the leading tumor type; now the concentration is explicit. That is a double-edged fact — it sharpens the germ cell opportunity the City of Hope interim data (due at a January testicular-cancer meeting) is designed to feed, but it also means the franchise leans heavily on one tumor type.

The things that went quiet

What management stops saying is often louder than what it starts. Three items from prior calls simply vanished. First, Norgine and Europe. On the March 2026 call the CFO was explicit: “we anticipate a material contribution to Fennec's financials in the second half of 2026 from Norgine.” — Robert Andrade, Chief Financial Officer · 2026-03-24 The second half is now here, and the Q3 script and Q&A contain no mention of Europe, PEDMARQSI, royalties, German pricing, or the milestone stack. Either the ex-U.S. ramp slipped or it is no longer worth narrating — but a promised second-half contributor going unmentioned in that second half is a flag worth logging. Second, Japan. This is the fourth consecutive call where licensing is "coming soon." “We are in discussions. We are actively in discussions. Our chief medical officer is in Japan today.” — Jeffrey S. Hackman, Chief Executive Officer · 2026-11-12 The persistence is real, but so is the pattern; a catalyst teased across four quarters starts to lose its power to move the stock. Third, business development remains the perennial maybe — "open to it," "haven't seen anything just yet." The expanded commercial footprint is still under-loaded with a second product.

What's already priced in

The tape tells its own story. Fennec peaked at $12.78 on August 11 — the day it reported the prior quarter — and has given back roughly 15% since, even though the trailing 90 days are still modestly positive. The market rallied into the Q2 print and de-rated afterward, exactly the pattern a decelerating sequential line would produce. The valuation has compressed accordingly: at roughly 6.4x trailing revenue, Fennec is no longer priced as a story but as a growing specialty-pharma launch, and the derived operating margin is the number that has to keep expanding for the multiple to hold. The quarter, then, is genuinely good and quietly complicated at once. The machine is working — record cash generation, a 30% EBITDA margin, a widening funnel — but the pace of revenue conversion is slowing just as the base gets harder, the ex-U.S. lever has gone mute, and the stock already gave back its report-day euphoria. The Q4 carryover is management's case that the 8% is a timing artifact rather than a trend; the next print is where that claim gets tested.